Wang Bolin, Huang Yan, Lin Tao
Weifang Medical University.
Department of Oncology, Affiliated Hospital of Weifang Medical University, Weifang, China.
Medicine (Baltimore). 2020 Jan;99(1):e18571. doi: 10.1097/MD.0000000000018571.
There is a growing literature on the significance of systemic immune-inflammation index in hepatocellular carcinoma. However, the results were inconsistent due to the small sample size and different study endpoints. Therefore, the purpose of this study was to further systematically and comprehensively verify the prognostic role of the SII in HCC.
Several databases were searched systematically, and relevant papers were selected. The main outcome measure was overall survival (OS); the secondary outcome measure was a composite of time to recurrence (TTR), progression-free survival (PFS), and recurrence-free survival (RFS).
Ten published retrospective studies involving 2796 HCC patients were included. The results revealed that elevated pre-treatment SII was related to lower OS (HR:1.54, P < .001) and earlier TTR (HR:1.77, P < .001).
Elevated SII is a poor prognostic factor for patients with hepatocellular carcinoma. The clinical application of SII is encouraged to evaluate the progress of hepatocellular carcinoma.
关于全身免疫炎症指数在肝细胞癌中的意义，相关文献日益增多。然而，由于样本量小和研究终点不同，结果并不一致。因此，本研究的目的是进一步系统全面地验证全身免疫炎症指数（SII）在肝癌中的预后作用。
系统检索多个数据库，并筛选相关论文。主要观察指标为总生存期（OS）；次要观察指标为复发时间（TTR）、无进展生存期（PFS）和无复发生存期（RFS）的综合指标。
纳入了10项已发表的回顾性研究，共2796例肝癌患者。结果显示，治疗前SII升高与较低的OS（HR：1.54，P＜0.001）和较早的TTR（HR：1.77，P＜0.001）相关。
SII升高是肝细胞癌患者的不良预后因素。鼓励将SII应用于临床以评估肝细胞癌的进展情况。
